Public and private pharmaceutical spending as determinants of health outcomes in Canada
Has this study been replicated?
The atlas records 1 reproduction of this study. Recorded outcomes: 1 mixed.
Reproductions
- A SECOND LOOK AT PHARMACEUTICAL SPENDING AS DETERMINANTS OF HEALTH OUTCOMES IN CANADA, Emmanuel Guindon & Contoyannis (2012). Health Economics. Outcome recorded: computation not checked, robustness challenges.
Robustness: In contrast with earlier findings, on the whole, no discernable relationship between spending on private or public pharmaceutical products and infant mortality or life expectancy at 65 is observed.
Outcome read from Robustness: abstract. View paper
Cite this record
Crémieux, P.-Y., Meilleur, M.-C., Ouellette, P., Petit, P., Zelder, M., & Potvin, K. (2004). Public and private pharmaceutical spending as determinants of health outcomes in Canada. Health Economics, 14(2), 107–116. Portico. https://doi.org/10.1002/hec.922
Other studies in the atlas
Failed replications · Successful replications · All browse pages